Hanssen Jaap L J, Stienstra Johan, Boers Stefan A, Pothast Cilia R, Zaaijer Hans L, Tjon Jennifer M, Heemskerk Mirjam H M, Feltkamp Mariet C W, Arend Sandra M
Department of Infectious Diseases, Leiden University Medical Center, C5-P, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Department of Internal Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Infect Dis Rep. 2021 Sep 27;13(4):855-864. doi: 10.3390/idr13040077.
It is not exactly clear yet which type of immune response prevails to accomplish viral clearance in coronavirus disease 2019 (COVID-19). Studying a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who suffered from COVID-19 provided insight in the immunological responses after treatment with COVID-19 convalescent plasma (CCP). Treatment consisted of oxygen, repeated glucocorticosteroids and multiple dosages of CCP guided by antibody levels. Retrospectively performed humoral and cellular immunity analysis made clear that not every serological test for COVID-19 is appropriate for follow-up of sufficient neutralizing antibodies after CCP. In retrospect, we think that CCP merely bought time for this patient to develop an adequate cellular immune response which led to viral clearance and ultimately clinical recovery.
目前尚不完全清楚在2019冠状病毒病（COVID-19）中哪种免疫反应占主导地位以实现病毒清除。对一名患有慢性淋巴细胞白血病和低丙种球蛋白血症且感染了COVID-19的患者进行研究，为了解COVID-19康复期血浆（CCP）治疗后的免疫反应提供了线索。治疗包括吸氧、反复使用糖皮质激素以及根据抗体水平给予多次剂量的CCP。回顾性进行的体液和细胞免疫分析表明，并非每项COVID-19血清学检测都适用于CCP治疗后足够中和抗体的随访。回顾来看，我们认为CCP只是为该患者争取了时间来产生足够的细胞免疫反应，从而导致病毒清除并最终实现临床康复。
